Adoptive immunotherapy of intracranial tumors by systemic transfer of tumor-draining lymph node cells (review)

International Journal of Oncology

Volumn 11, Issue 2, 1997, Pages 389-395

  Plautz, Gregory E ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Brain neoplasm; Clinical trial; T cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; EFFECTOR CELL; INTRACRANIAL TUMOR; LYMPH NODE CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION;

EID: 0030787016     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.2.389     Document Type: Article

References (18)

1. Walker MD, Alexander E and Hunt WE: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative trial. J Neurosurg 49: 333-343, 1978.
2. Walker MD, Green SB, Byar DP, Alexander EJ, Batzdorf U, Hunt WE, MacCarty CS, Mahaley MSJ, Mealy JJ, Owens G, Ransahoff JI, Robertson JT, Shapiro WR, Smith KRJ, Wilson CB and Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303: 1323-1329, 1980.
3. Mitchison NA: Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 102: 157-177, 1955.
4. Prehn RT and Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769-778, 1957.
5. Urban JL and Schreiber H: Tumor antigens. Annu Rev Immunol 10: 617-644, 1992.
6. Rosenau W and Morton DL: Tumor-specific inhibition of growth of methylcholanthrene-induced sarcomas in vivo and in vitro by sensitized isologous lymphoid cells. J Natl Cancer Inst 36: 825-836, 1966.
7. Fefer A: Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res 29: 2177-2183, 1969.
8. Wespic HT, Zbar B, Rapp HJ and Borsos T: Systemic transfer of tumor immunity: delayed hypersensitivity and suppression of tumor growth. J Natl Cancer Inst 44: 955-963, 1970.
9. Borberg H, Oettgen HF, Chondry F and Beattie EJ Jr: Inhibition of established transplants of chemically induced sarcomas in syngenic mice by lymphocytes from immunized donors. Int J Cancer 10: 539-547, 1972.
10. Smith HG, Harmel RP, Hanna MG Jr, Zwillig BS, Zbar B and Rapp HJ: Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J Natl Cancer Inst 58: 1315-1322, 1977.
11. Medawar PW: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29: 58-69, 1948.
12. Head JR and Griffin WST: Functional capacity of solid tissue implants in the brain: evidence for immunological privilege. Proc Roy Soc 224: 375-387, 1985.
13. Fontana A and Fierz W: The endothelium-astrocyte immune control system of the brain. Semin Immunopathol 8: 57-70, 1985.
14. Lampson LA and Hickey WF: Monoclonal antibody analysis of the MHC expression in human brain biopsies. J Immunol 136: 4054-4062, 1986.
15. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Decker K, Muller C and Tschopp J: Fas and fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335-343, 1996.
16. Jacobs SK, Wilson DJ, Kornblith PL and Grimm EA: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64: 743-749, 1986.
17. Merchant RE, Merchant LH, Cook SHS, McVicar DW and Young HF: Intralesional infusion of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725-732, 1988.
18. Yoshida S, Tanaka R, Takai N and Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 48: 5011-5016, 1988.